All about pain pharmacology: what pain physicians should know

키워드

참고문헌 (59)

1. Merskey H, "Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy", Pain, 6, pp.249~252 (1979)
2. Jensen TS, "Translation of symptoms and signs into mechanisms in neuropathic pain", Pain, 102, pp.1~8 (2003)
3. Baron R, "Peripheral neuropathic pain : a mechanism-related organizing principle based on sensory profiles", Pain, 158, pp.261~272 (2017)
4. Attal N, "Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion?", Pain, 138, pp.343~353 (2008)
5. Bouhassira D, "Development and validation of the neuropathic pain symptom inventory", Pain, 108, pp.248~257 (2004)
6. Loeser JD, "The Kyoto protocol of IASP basic pain terminology", Pain, 137, pp.473~477 (2008)
7. Kallakuri S, "Demonstration of substance P, calcitonin gene-related peptide, and protein gene product 9.5 containing nerve fibers in human cervical facet joint capsules", Spine (Phila Pa 1976), 29, pp.1182~1186 (2004)
8. Park SC, "Effect of adding cervical facet joint injections in a multimodal treatment program for long-standing cervical myofascial pain syndrome with referral pain patterns of cervical facet joint syndrome", J Anesth, 26, pp.738~745 (2012)
9. 김태균, "Percutaneous Vertebroplasty and Facet Joint Block", Journal of Korean Medical Science, 20(6), pp.1023~1028 (2005), 대한의학회
10. 김경훈, "Cervical Facet Joint Injections in the Neck and Shoulder Pain", Journal of Korean Medical Science, 20(4), pp.659~662 (2005), 대한의학회
11. Demondion X, "The posterior lumbar ramus : CT-anatomic correlation and propositions of new sites of infiltration", AJNR Am J Neuroradiol, 26, pp.706~710 (2005)
12. Danelich IM, "Safety of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease", Pharmacotherapy, 35, pp.520~535 (2015)
13. Handin RI, "The history of antithrombotic therapy : the discovery of heparin, the vitamin K antagonists, and the utility of aspirin", Hematol Oncol Clin North Am, 30, pp.987~993 (2016)
14. Smith DK, "Aspirin for primary prevention : USPSTF recommendations for CVD and colorectal cancer", J Fam Pract, 68, pp.146~151 (2019)
15. MacKintosh ML, "Prevention strategies in endometrial carcinoma", Curr Oncol Rep, 20, pp.101~ (2018)
16. Serrano D, "Therapeutic cancer prevention : achievements and ongoing challenges-a focus on breast and colorectal cancer", Mol Oncol, 13, pp.579~590 (2019)
17. Hurwitz LM, "Aspirin and non-aspirin NSAID use and prostate cancer incidence, mortality, and case fatality in the atherosclerosis risk in communities study", Cancer Epidemiol Biomarkers Prev, 28, pp.563~569 (2019)
18. Vane JR, "The mechanism of action of aspirin", Thromb Res, 110, pp.255~258 (2003)
19. Botting RM, "Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology", Pharmacol Rep, 62, pp.518~525 (2010)
20. Tosco P, "Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin", ChemMedChem, 4, pp.939~945 (2009)
21. Lucido MJ, "Crystal structure of aspirin-acetylated human cyclooxygenase-2 : insight into the formation of products with reversed stereochemistry", Biochemistry, 55, pp.1226~1238 (2016)
22. Chiang N, "Aspirin triggers formation of antiinflammatory mediators : new mechanism for an old drug", Discov Med, 4, pp.470~475 (2004)
23. Brune K, "Acetaminophen", paracetamol: a history of errors, failures and false decisions, 2015, pp.19, 953~965
24. Graham GG, "The modern pharmacology of paracetamol : therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings", Inflammopharmacology, 21, pp.201~232 (2013)
25. Candido KD, "Pharmacology of acetaminophen, nonsteroidal antiinflammatory drugs, and steroid medications : implications for anesthesia or unique associated risks", Anesthesiol Clin, 35, pp.e145~62 (2017)
26. Schildknecht S, "Acetaminophen inhibits prostanoid synthesis by scavenging the PGHS-activator peroxynitrite", FASEB J, 22, pp.215~224 (2008)
27. Aminoshariae A, "Acetaminophen : old drug, new issues", J Endod, 41, pp.588~593 (2015)
28. Smith HS, "Potential analgesic mechanisms of acetaminophen", Pain Physician, 12, pp.269~280 (2009)
29. Sasaki F, "The leukotriene receptors as therapeutic targets of inflammatory diseases", Int Immunol, 31, pp.607~615 (2019)
30. Vyvey M, "Steroids as pain relief adjuvants", Can Fam Physician, 56, pp.1295~1297 (2010)
31. Tager AM, "BLT1 and BLT2 : the leukotriene B(4)receptors", Prostaglandins Leukot Essent Fatty Acids, 69, pp.123~134 (2003)
32. Pathan H, "Basic opioid pharmacology : an update", Br J Pain, 6, pp.11~16 (2012)
33. Kreek MJ, "Pharmacotherapy in the treatment of addiction : methadone", J Addict Dis, 29, pp.200~216 (2010)
34. 옥회경, "Can oliceridine (TRV130), an ideal novel μ receptor G protein pathway selective (μ-GPS) modulator, provide analgesia without opioid-related adverse reactions?", The Korean Journal of Pain, 31(2), pp.73~79 (2018), 대한통증학회
35. Jensen TS, "Allodynia and hyperalgesia in neuropathic pain : clinical manifestations and mechanisms", Lancet Neurol, 13, pp.924~935 (2014)
36. Bennett MI, "Using screening tools to identify neuropathic pain", Pain, 127, pp.199~203 (2007)
37. Cruccu G, "Tools for assessing neuropathic pain", PLoS Med, 6, pp.e1000045~ (2009)
38. Krause SJ, "Development of a neuropathic pain questionnaire", Clin J Pain, 19, pp.306~314 (2003)
39. Bouhassira D, "Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire(DN4)", Pain, 114, pp.29~36 (2005)
40. Bennett M, "The LANSS Pain Scale : the Leeds assessment of neuropathic symptoms and signs", Pain, 92, pp.147~157 (2001)
41. Portenoy R, "Development and testing of a neuropathic pain screening questionnaire : ID Pain", Curr Med Res Opin, 22, pp.1555~1565 (2006)
42. Freynhagen R, "painDETECT : a new screening questionnaire to identify neuropathic components in patients with back pain", Curr Med Res Opin, 22, pp.1911~1920 (2006)
43. Obermann M, "Treatment options in trigeminal neuralgia", Ther Adv Neurol Disord, 3, pp.107~115 (2010)
44. Di Stefano G, "Current and innovative pharmacological options to treat typical and atypical trigeminal neuralgia", Drugs, 78, pp.1433~1442 (2018)
45. Montano N, "Advances in diagnosis and treatment of trigeminal neuralgia", Ther Clin Risk Manag, 11, pp.289~299 (2015)
46. Headache Classification Subcommittee of the International Headache Society, "The international classification of headache disorders: 2nd edition", Cephalalgia, 24(Suppl 1), pp.9~160 (2004)
47. Fricke-Galindo I, "Carbamazepine adverse drug reactions", Expert Rev Clin Pharmacol, 11, pp.705~718 (2018)
48. Schmidt D, "What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?", Epilepsy Behav, 5, pp.627~635 (2004)
49. Zhou M, "Oxcarbazepine for neuropathic pain", Cochrane Database Syst Rev, 12, pp.CD007963~ (2017)
50. Senderovich H, "Is there a role for combined use of gabapentin and pregabalin in pain control? Too good to be true?", Curr Med Res Opin, 34, pp.677~682 (2018)
51. Kim ES, "Gabapentin enacarbil : a review in restless legs syndrome", Drugs, 76, pp.879~887 (2016)
52. 양종연, "Administration of four different doses of gabapentin reduces awakening from breakthrough pain and adverse effects in outpatients with neuropathic pain during the initial titration", Korean Journal of Anesthesiology, 65(1), pp.48~54 (2013), 대한마취통증의학회
53. Serpell M, "Neuropathic pain responds better to increased doses of pregabalin : an in-depth analysis of flexible-dose clinical trials", J Pain Res, 10, pp.1769~1776 (2017)
54. Domon Y, "Binding characteristics and analgesic effects of mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels", J Pharmacol Exp Ther, 365, pp.573~582 (2018)
55. Javed S, "Mirogabalin and emerging therapies for diabetic neuropathy", J Pain Res, 11, pp.1559~1566 (2018)
56. 김경훈, "Rediscovery of Nefopam for the Treatment of Neuropathic Pain", The Korean Journal of Pain, 27(2), pp.103~111 (2014), 대한통증학회
57. Max MB, "Bonica's management of pain", pp.1710~1726 (2000), Lippincott Williams & Wilkins
58. 최윤미, "Etifoxine for Pain Patients with Anxiety", The Korean Journal of Pain, 28(1), pp.4~10 (2015), 대한통증학회
59. Sang Wook Shin, "Antipsychotics for patients with pain", The Korean Journal of Pain, 32(1), pp.3~11 (2019), 대한통증학회[DOI]

관련 논문AI추천